Previous Close | 28.55 |
Open | 28.42 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 28.42 - 28.59 |
52 Week Range | 28.03 - 67.80 |
Volume | |
Avg. Volume | 33,281 |
Market Cap | 28.088B |
Beta (5Y Monthly) | 0.97 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.27 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.12 (0.42%) |
Ex-Dividend Date | Apr 29, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for BAYZF
Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now. Bayer CEO Bill Anderson says, "This is not a good time to be... breaking up the firm," given the company's need to rebuild its pharmaceutical pipeline and battle the ongoing litigation stemming from the weedkiller Roundup. When it comes to the Roundup lawsuits, Bayer has "adequately provisioned" for the costs of those suits, Anderson says. Overall, "the fundamental fact is, that glyphosate, Roundup, is safe," Anderson states, adding that Bayer is "a scientifically-driven company and we have this litigation thing that's not scientific." On the pharmaceutical business, Anderson says the group is "in a bit of a transition phase." "We got a couple of major medicines that are losing patent protection over the next few years. So we are busy rebuilding the pipeline right now," he tells Yahoo Finance. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.
Alongside other sectors of the consumer economy, nonprescription drug prices saw prices rise 9.3% year-over-year. The insurance industry, health insurance and auto insurance providers in particular, have been beset by inflationary challenges. Yahoo Finance Health Reporter Anjalee Khemlani details the price trends for over-the-counter drugs, referencing a statement from Bayer (BAYRY) from its third-quarter 2023 in relation to how pharmaceutical companies are trying to offset inflation. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.
Bayer rejected on Tuesday a claim by a Brazilian farmers' lobby group that the country's top court had ordered the diversified German company to return about $2 billion in royalties to soybean farmers. The case, which is related to a law dispute in Brazil about extensions of patents for more than 20 years, is the latest chapter of a protracted battle between Bayer and Brazilian farmers, who have launched multiple legal challenges against the company. Mato Grosso state farmer lobby Aprosoja-MT said in a statement the Supreme Court ordered Bayer on Tuesday to return to farmers royalties they have paid since 2018 related to two patents of genetically modified organism known as Intacta RR2 PRO.